Výsledky vyhledávání

Akademický článek

Diagnosis, testing, treatment, and outcomes among patients with advanced non‐small cell lung cancer in the United States

Autor: Mo Yang, Joanna P. MacEwan, Sai Sriteja Boppudi, Monica R. McClain, Richard M. O'Hara Jr, Paul K. Paik

Publikováno v: Cancer Medicine, Vol 12, Iss 24, Pp 21605-21614 (2023)

Abstract Introduction Characteristics of patients in clinical trials may differ from those of real‐world patients. Our objective was to describe biomarker testing and outcomes among patients with advanced non‐small cell lung cancer (aNSCLC) in a

Externí odkaz: https://doaj.org/article/cae17f97ca924a338f77e6f7e6945e2f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas

Autor: Paul K. Paik, Jia Luo, Ni Ai, Rachel Kim, Linda Ahn, Anup Biswas, Courtney Coker, Wanchao Ma, Phillip Wong, Darren J. Buonocore, W. Victoria Lai, Jamie E. Chaft, Swarnali Acharyya, Joan Massagué, Mark G. Kris

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-8 (2022)

Generation of TNF-α in response to chemotherapy has been associated with chemo-resistance and metastasis propagation. Here the authors show that the combination of an anti-TNF antibody and cisplatin doublet chemotherapy increases anti-tumor efficacy

Externí odkaz: https://doaj.org/article/03426524a16147d1b39e9e33d5c9e351

Zobrazit plný text záznamu

Akademický článek

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-9 (2021)

There is an unmet clinical need for simple, accessible biomarkers to select patients who are more likely to respond to immune checkpoint therapy. Here the authors show that a lower neutrophil-to-lymphocyte ratio is associated with better overall and

Externí odkaz: https://doaj.org/article/dd218269962540ee8add1e4fa781b7e2

Zobrazit plný text záznamu

Akademický článek

Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer

Autor: Leo Y. Luo, MD, Robert M. Samstein, MD, PhD, Rosalind Dick-Godfrey, Baho Sidiqi, Chunyu Wang, Federica Oro, Mark Sonnick, MD, Paul K. Paik, MD, Jamie E. Chaft, MD, Narek Shaverdian, MD, Daniel R. Gomez, MD, Andreas Rimner, MD, Abraham J. Wu, MD

Publikováno v: Advances in Radiation Oncology, Vol 6, Iss 1, Pp 100615- (2021)

Background: Radiation with platinum-based chemotherapy is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). Despite aggressive treatment, progression-free survival and overall survival remain poor. It is unclear whet

Externí odkaz: https://doaj.org/article/0b86beb5e984404499f5e841612193ee

Zobrazit plný text záznamu

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Autor: Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal, Sara A. Hayes, Andrew J. Plodkowski, Paul K. Paik, Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Franziska Michor, Helena A. Yu

Publikováno v: Clinical Cancer Research. 29:1423-1428

Purpose: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54f4f625ed5f97d1b7e414751e5f95a4
https://doi.org/10.1158/1078-0432.ccr-22-3484

Zobrazit plný text záznamu

Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Autor: Paul K Paik, Ravi K Goyal, Beilei Cai, Mark A Price, Keith L Davis, Valerie Derrien Ansquer, Nydia Caro, Teddy R Saliba

Publikováno v: Future Oncology. 19:217-228

Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Material

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f8beb36594f1412c9850d5daf4732bc
https://doi.org/10.2217/fon-2022-1133

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání